Financial cycles of acquisition and ‘buybacks’ threaten public access to breakthrough drugs

An analysis of a new drug’s journey to market shines a light on financial practices that see some major pharmaceutical companies relying on a cycle of acquisitions, profits from high prices, and shareholder-driven maneuvers that threatens access to medicines for current and future patients.